SELLAS Life Sciences Group, Inc. filed a Form 8-K on November 17, 2026, disclosing positive topline results from the pivotal Phase 3 REGAL trial evaluating galinpepimut-S in patients with acute myeloid leukemia.

Key Highlights

  • Primary endpoint met: The REGAL trial met its primary endpoint of overall survival, with a statistically significant and clinically meaningful improvement compared with investigator's choice of best available treatment.
  • 41% reduction in risk of death: Galinpepimut-S demonstrated a hazard ratio of 0.59, with a two-sided p=0.035.
  • Median OS of 24.0 months: GPS-treated patients achieved a median overall survival of 24.0 months versus 14.7 months with best available treatment.
  • Patient population: The trial enrolled patients in second or later complete remission who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.
  • Safety profile: Treatment-related adverse events were predominantly mild to moderate (grade 1/2), most commonly local injection site reactions, with no new safety signals identified.

SELLAS Reports Phase 3 REGAL Trial Results for GPS in AML

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) disclosed the topline results of its pivotal randomized Phase 3 REGAL trial via a current report filed November 17, 2026, under Items 7.01 and 8.01. According to the filing, the trial evaluated galinpepimut-S ("GPS"), described as "an immunotherapeutic cancer vaccine," as maintenance monotherapy in patients with acute myeloid leukemia ("AML") who achieved a second or later complete remission (CR2 or later) or complete remission with insufficient platelet recovery (CRp2 or later) following second- or later-line salvage therapy.

The filing states that the REGAL trial met its primary endpoint of overall survival. GPS demonstrated a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p=0.035. The company reported a median overall survival of 24.0 months among GPS-treated patients compared with 14.7 months among patients receiving investigator's choice of best available treatment ("BAT").

According to the filing, GPS "was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals identified." Treatment-related adverse events were predominantly grade 1/2, with local injection site reactions as the most common occurrence. The filing also noted that both treatment arms were well balanced for prognostic stratification factors, and that patients who proceeded to hematopoietic stem cell transplantation were limited in number and equally distributed between the study arm and the control arm. The press release announcing these results was attached as Exhibit 99.1 to the filing.

What Was Disclosed

SELLAS Life Sciences Group filed an 8-K on November 17, 2026, reporting that its Phase 3 REGAL trial for GPS in AML met its primary overall survival endpoint, with GPS showing a hazard ratio of 0.59 and a median OS of 24.0 months versus 14.7 months for best available treatment.